Jay Bradner has recruited a marquee oncology drug researcher into the ranks of the Novartis Institutes for BioMedical Research. Alice Shaw is jumping from prestigious posts intertwined through Mass General, Harvard and Dana-Farber to take the lead of NIBR’s translational clinical oncology group.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

What differentiates a woman leader in biopharma R&D from a man?

Not much, except there are fewer of them in senior posts. Data suggest women are not more risk-averse, family-oriented or less confident than their male counterparts — indeed the differences between the two sexes are negligible. But a glance at the top R&D positions in Big Pharma leaves little doubt that upward migration in the executive ranks of biopharma R&D is tough.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

An in-house FDA review of Amarin’s Vascepa raises a set of hurdles the biotech will have to clear if the biotech expects to get the long-awaited FDA approval that could set it on a path to superstar status. But it appears that Amarin has survived another potential setback without introducing a major new threat to its prospects.

The stakes don’t get much higher, with analysts saying a win this week for Amarin could lead to billions in new sales — provided the agency stamps it with an OK. And investors liked what they say in the FDA review this morning, bumping the stock $AMRN 17%.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

Solid Biosciences continues to be plagued by safety issues.

Close to 18 months after the gene therapy biotech was able to quickly shed an FDA hold on their lead Duchenne muscular dystrophy program for SGT-001, regulators have stepped back in to force another halt after another patient was hit hard by a set of serious adverse events remarkably similar to the first set.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

French newspapers are reporting that Merck is shuttering a research center in central France and scaling back on its manufacturing operations in the area, laying off more than 200 staffers in the process.

La Montagne reported that the move will eliminate 106 research jobs, with more than 100 manufacturing positions on the chopping block as well.

I have a query into Merck but did not hear back immediately.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN

NextCure’s turn as the Cinderella of cancer-focused biotechs was short-lived.
Just a few days after its shares $NXTC zoomed up more than 250% on some very early stage results in a SITC abstract, a more complete analysis over the weekend spiked the hype and left investors in high dudgeon as the stock price collapsed back towards earth Monday.
The focus at NextCure is centered on NC318, an antibody that is intended to shut down the immunosuppressive Siglec-15 — or S-15 — target. After adding a small group of patients to the readout, investigators circled 2 clinical responses, a complete and partial response, along with 4 stable disease cases in non-small cell lung cancer.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,100+ biopharma pros reading Endpoints daily — and it's free.

SUBSCRIBE SIGN IN